Mus musculus
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA362328 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR5184320_1.fastq.gz | Fastqsanger.gz | |||
| SRR5184320_2.fastq.gz | Fastqsanger.gz | |||
| SRR5184330_1.fastq.gz | Fastqsanger.gz | |||
| SRR5184330_2.fastq.gz | Fastqsanger.gz | |||
| SRR5184321_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 76 |
Similar Datasets
Project description:We report the presence of the C11orf95-RELA fusion in cells isolated from a patient presenting with anaplastic ependymoma
2019-08-29 | GSE136559 | GEO
Project description:Over 60% of supratentorial (ST) ependymomas harbor a ZFTA-RELA (ZRfus) gene fusion (formerly C11orf95-RELA). To study the biology of ZRfus, we developed an autochthonous mouse tumor model using in utero electroporation (IUE) of the embryonic mouse brain. Integrative epigenomic and transcriptomic mapping was performed on IUE driven ZRfus tumors by CUT&RUN, ChIP, ATAC, and RNA sequencing and compared to human ZRfus driven ependymoma. In addition to direct canonical NF-kB pathway activation, ZRfus dictates a neoplastic transcriptional program and binds to thousands of unique sites across the genome that are enriched with Plagl family transcription factor (TF) motifs. ZRfus activates gene expression programs through recruitment of transcriptional co-activators (Brd4, Ep300, Cbp, Pol2) that are amenable to pharmacologic inhibition. Downstream ZRfus target genes converge on developmental programs marked by Plagl transcription factor proteins, and activate neoplastic programs enriched in Mapk, focal adhesion, and gene imprinting networks.
2021-03-29 | GSE161679 | GEO
Project description:To profile H3K4me3Q5Ser (5HT-H3) distribution in mouse ZFTA-RELA ependymoma tumors Furthermore, we also sought to examine H3K27ac and H3K27me3 distribution in mouse ZFTA-RELA ependymoma versus ETV5 overexpressing tumors
2024-06-03 | GSE246032 | GEO
Project description:To profile gene expression differences between mouse non-tumor cortex versus ZFTA-RELA ependymoma versus ETV5 overexpressing tumors Furthermore, we also sought to profile gene expression differences between ZFTA-RELA ependymoma versus NPY overexpressing tumor
2024-06-03 | GSE246031 | GEO
Project description:The NFκB family of transcription factors is a major regulator of the innate immune responses, and its dysregulation has been linked to several inflammatory diseases. In this study we focused on bone marrow derived macrophages from the recently described p65-DsRed/IκBα-eGFP transgenic strain, in which a human copy of RelA (p65) was introduced into the mouse genome. Confocal imaging analysis showed that the human RelA is expressed these cells and can translocate to the nucleus upon Toll-like receptor 4 activation (TLR4). RNA sequencing analysis of polysaccharide-stimulated macrophage cultures, revealed that the extra copy of human RelA impacts on gene transcription, affecting both NFκB and non-NFκB target genes, including immediate-early and late response NFκB target genes, such as Fos and Cxcl10, respectively. In validation experiments on NFB targets we observed reduced mRNA levels, but similar expression kinetic profile of the transgenic cells compared to the wild type. Enrichment pathway analysis based on the differentially regulated genes revealed that interferon and cytokine signaling, are affected downstream TLR4. These immune response pathways were also affected when the macrophages were treated with tumor necrosis factor. The impact of genetic manipulation on cell-specific functions is particularly important and highlights the need of understanding the molecular basis on which complicated in vitro and in vivo experiments will be designed on.
2022-03-22 | E-MTAB-11461 | biostudies-arrayexpress
Project description:The epigenome defines the cell type, but also possesses plasticity to tune gene expression in the context of extracellular cues. This tuning is evident in immune sentinel cells such as macrophages, which respond to pathogens and cytokines with phenotypic shifts driven by epigenomic reprogramming. Recent studies indicate that this reprogramming arises from the activity of transcription factors including nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB). NFκB binds not only to available enhancers but may also produce de novo enhancers in previously silent areas of the genome. Here, we show that NFκB reprograms the macrophage epigenome in a stimulus-specific manner, in response only to a subset of pathogen-derived stimuli. The basis for these surprising differences lies in the stimulus-specific temporal dynamics of NFκB activity. In response to different stimuli, NFκB enters the nucleus with variable speed, amplitude, and duration, and may oscillate between the nucleus and cytoplasm. These dynamical features combine to specify the identity and dose of a given stimulus. We demonstrate through live cell imaging, mathematical modeling, and genetic perturbations that NFκB promotes open chromatin and formation of de novo enhancers most strongly when its dynamics are non-oscillatory. These de novo enhancers result in the activation of additional response genes. We propose a mechanistic paradigm in which the temporal dynamics of transcription factors are a key determinant of their capacity to control epigenomic reprogramming, thus enabling the formation of stimulus-specific memory in innate immune sentinel cells.
2021-01-01 | GSE146068 | GEO
Project description:Ependymomas exist within distinct genetic subgroups, but the molecular diversity within individual ependymomas is unknown. We performed multiplatform molecular profiling of 6 spatially-distinct samples from an ependymoma with C11orf95-RELA fusion. DNA methylation and RNA sequencing distinguished clusters of samples according to neuronal development gene expression programs that could also be delineated by differences in magnetic resonance blood perfusion. Exome sequencing and phylogenetic analysis revealed epigenomic intratumor heterogeneity, and suggested that chromosomal structural alterations may precede accumulation of single nucleotide variants during ependymoma tumorigenesis. In sum, these findings shed new light on the oncogenesis and intratumor heterogeneity of ependymoma.
2019-12-20 | GSE142320 | GEO
Project description:Pediatric ependymoma has relatively low frequencies of DNA mutations, which suggest that epigenetics may drive tumors. However, the epigenetic mechanisms for recurrent ependymoma are still poorly understood. Here, we performed longitudinal and comprehensive DNA methylation and gene expression analysis for recurrent pediatric ependymoma tumors from 10 patients, total 46 DNA methylomes (including primary tumors and matched recurrent tumors; normal pediatric brain tissues and PDOX tumors). Both RELA and PFA tumors maintained the subtype DNA methylation signatures during repeated relapses. We further identified the potential DNA methylation predictors, drivers and boosters and their potential regulated genes for recurrent ependymoma tumors. Increased DNA methylation levels within H3K4me1 enriched regions indicates disturbed functions of LSD1 gene in recurrent ependymoma tumors. Combining novel LSD1 inhibitor SYC-836 with radiation (XRT) significantly prolonged animal survival times in PDOX models of recurrent PFA ependymoma. Our PDOX models provide a unique platform for preclinical testing drugs and development of new therapy for pediatric recurrent ependymoma.
2022-07-12 | GSE156619 | GEO
Project description:Nuclear condensates of YAP fusion proteins as a critical driver for ependymoma
| PRJNA857085 | ENA
Project description:A systems-level pharmacoproteomics study of a standardized murine model of toll-like receptor (TLR)3-NFκB/RelA innated inflammation in the absence or presence of a highly selective Brd4 (ZL0454) or nonselective Bromodomain and Extraterminal domain inhibitor (JQ1).
2019-07-16 | PXD012060 | Pride